

### AMENDMENTS TO THE CLAIMS

1. (Original) A large scale storage system of viable somatic stem and/or progenitor cells suitable for use in a method of treatment of a disease or a disorder of a patient, or a method of treatment of a patient having a predisposition for a disease or disorder, comprising:
  - a) a large number of solid supports comprising viable somatic stem and/or progenitor cells from patients, and,
  - b) preoperative information of the patients from which the cells have been taken.
2. (Original) The system according to claim 1, wherein the cryopreserved/frozen viable somatic stem and/or progenitor cells are made through a method comprising the steps of:
  - a) isolating or obtaining (pre-natal, neonatal or post-natal) tissue from a patient comprising somatic stem and/or progenitor cells,
  - b) separating the stem and/or progenitor cells from said tissue, and,
  - c) cryopreserving/freezing the cells of step b) in a solid support such that said cells remain(s) viable.
3. (Currently amended) A method of treatment of a disease or a disorder of a patient, or a method of treatment of a patient having a predisposition for a disease or disorder, comprising thawing tissue comprising somatic stem and/or progenitor cells or thawing isolated stem and/or progenitor cells from patients obtained by means of a large scale storage system of claim 1 ~~or 2~~ and administering said stem and/or progenitor cells to said patient.
4. (Currently amended) The system ~~or method according to any of claims 1 to 3~~ according to claim 1, wherein said solid support is marked by a barcode.
5. (Currently amended) The system ~~or method according to any of claims 1 to 4~~ according to claim 2, wherein said tissue is isolated from remote areas of the body of the patient.

Int'l Appl. No. : PCT/EP2005/002094

Int'l filing date : February 28, 2005

6. (Currently amended) The system ~~or method~~ according to ~~any of claims 1 to 5~~ according to claim 2, wherein said tissue ~~may be chosen~~ is selected from the group consisting of bone marrow, blood and fat tissue.

7. (Currently amended) The system ~~or method~~ according to claim 6, wherein said bone marrow is isolated from hip bones.

8. (Currently amended) The system ~~or method~~ according to ~~any of claims 1 to 7~~ according to claim 2, wherein the patient from which the tissue is taken is an adult.

9. (Currently amended) The ~~system or method~~ according to ~~any of claims 3 to 8~~ system according to claim 2, wherein said cells or tissue are/is further treated using stem cell technologies.

10. (Currently amended) The ~~system or method~~ according to ~~any of claims 3 to 9~~ method according to claim 3, wherein said cells or tissue are/is further differentiated.

11. (Currently amended) The ~~system or method~~ according to claim 10, wherein the differentiated cells/tissue are/is ~~chosen~~ selected from the group consisting of neuronal, liver, islet and heart cells/tissue.

12. (Currently amended) A product comprising a plurality of viable somatic stem and/or progenitor cells combined with preoperative information of ~~the~~ a patient from which said somatic stem and/or progenitor cells have been taken.

13. (Currently amended) ~~A~~ The product according to claim 12, wherein said somatic stem and/or progenitor cells carry a heterologous gene sequence for use in the treatment or prevention of ~~the~~ human disease or disorder or a predisposition thereof, said gene sequence being stably incorporated in said cells, said cells being capable of generating progeny cells which express the heterologous gene sequence.

Int'l Appl. No. : PCT/EP2005/002094  
Int'l filing date : February 28, 2005

14. (Currently amended) ~~A method of treatment of a disease or a disorder of a patient or a method of treatment of a patient having predisposition for a disease or disorder comprising the use of a product according to claim 12 or 13 or a system according to any of claims 1 to 11, or a~~  
The method according to claim 3, wherein said disease or disorder is chosen selected from the  
group consisting of:

- a) leukemia and related cancers such as lymphoma,
- b) damages to heart cells and heart vessels, such as those following acute myocardial infarction (heart attack), congestive heart disease, or other heart ailments for example unstable angina pectoris,
- c) brain and spinal cord neurological damage (eg. Parkinson's disease and Alzheimer Disease),
- d) stroke, and,
- e) diabetes (develop islet cells).

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Currently amended) ~~The system, method or product~~method according to ~~any of claims 1 to 20~~claim 3, wherein said patient is treated with autologous cells.

22. (Original) A method for the preservation of viable postnatal stem and/or progenitor cells for use in a method of treatment of a disease or a disorder of a patient, comprising the steps of:

- a) isolating post-natal tissue from a patient comprising stem and/or progenitor cells,
- b) optionally, separating the stem cells and/or progenitor cells from said postnatal tissue, and,

Int'l Appl. No. : PCT/EP2005/002094  
Int'l filing date : February 28, 2005

c) cryopreserving/freezing the tissue of step a) or the cells of step b) in a solid support such that said tissue or cells remain(s) viable.

23. (Currently amended) ~~A method for obtaining postnatal stem and/or progenitor cells for use in a method of treatment of a disease or a disorder of a patient, comprising the steps of:~~  
a) ~~isolating postnatal tissue from a patient comprising stem and/or progenitor cells,~~  
b) ~~optionally, separating the stem and/or progenitor cells from said postnatal tissue,~~  
c) ~~cryopreserving/freezing the tissue of step a) or the cells of step b) in a solid support such that the tissue or cells remain(s) viable, and,~~ The method according to claim 22, further comprising  
d) thawing said tissue or cells.

24. (Currently amended) The method according to claim 22 ~~or 23~~, wherein said solid support is marked by a barcode.

25. (Currently amended) The method according to ~~any of claims 22 to 24~~ claim 22, wherein said postnatal tissue is isolated from remote areas of the body of the patient.

26. (Currently amended) The method according to ~~any of claims 22 to 24~~ claim 22, wherein said postnatal tissue is isolated from ~~the group consisting of bone marrow, blood and or fat~~ tissue.

27. (Original) The method according to claim 26, wherein said bone marrow is isolated from hip bones.

28. (Currently amended) The method according to ~~any of claims 22 to 27~~ claim 22, wherein the patient from which the postnatal tissue is taken is an adult.

29. (Currently amended) The method according to ~~any of claims 23 to 28~~ claim 22, wherein said cells or tissue are/is further treated using stem cell technologies.

Int'l Appl. No. : PCT/EP2005/002094  
Int'l filing date : February 28, 2005

30. (Currently amended) The method according to ~~any of claims 23 to 29~~claim 23, wherein said cells or tissue are/is further differentiated.

31. (Original) A system of preserved viable post-natal stem and/or progenitor cells for the use in a method of treatment of a disease or a disorder of a patient, comprising:  
a) (a) solid support(s) comprising cryopreserved/frozen viable post-natal stem and/or progenitor cells from one or more patients, and,  
b) preoperative information of the patient(s) from which the postnatal tissue(s) has/have been taken.

32. (Currently amended) A product comprising a plurality of viable postnatal stem and/or progenitor cells obtained by a method according to ~~any of claims 22 to 30~~claim 22.

33. (Currently amended) The product according to claim 32, wherein said cells carry a heterologous gene sequence, ~~said gene sequence being of use in the treatment or prevention of the human disease or disorder~~which is stably incorporated in said cells, said cells being capable of generating progeny cells which express the heterologous gene sequence.

34-41. (Cancelled)